Treatment Details – 9.3 months
|Patients: This Phase II study involved 37 patients with malignant pleural mesothelioma who had not received chemotherapy or biological therapy before.|
Treatment: The treatment consisted of the chemotherapy drugs cisplatin (platinol) and doxorubicin (adriamycin) with alpha-2b interferon.
Toxicity: Grade 4 toxicities included hematologic and renal.
Results: The median survival was 9.3 months.
Correspondence: Hector Soto Parra